Tacrolimus市場：按產品類型、應用、最終用戶和地區分類

2026年Tacrolimus市場規模估計為127億美元，預計2033年將達到166億美元。預計2026年至2033年，其複合年成長率將達7.2%。

Tacrolimus是一種Calcineurin抑制劑，也是一種強效免疫抑制劑，主要用於預防器官移植後的細胞排斥。它還可局部用於治療重度異位性皮膚炎、骨髓移植後難治性重度葡萄膜炎以及白斑症（一種皮膚病）。Tacrolimus以膠囊劑、口服懸浮液顆粒劑（需與液體混合服用）、緩釋膠囊劑和緩釋片上市，供口服。速釋型Tacrolimus獲準與其他免疫抑制劑合併使用，用於預防接受同種異體肝、腎、心臟或肺移植的成人和兒童患者的器官排斥反應。緩釋型Tacrolimus核准與其他免疫抑制劑合併使用，用於核准接受腎臟移植的成人和兒童患者的器官排斥反應，也可用於從速釋製劑換成緩釋製劑的患者。

市場動態

預計市場主要企業不斷推出新產品將推動預測期內市場成長。例如，2020年6月，諾華旗下業務部門、全球領先的學名藥商山德士宣布，其每日一次的Tacrolimus非專利膠囊在德國、英國、荷蘭、芬蘭、瑞典、愛沙尼亞、拉脫維亞和斯洛伐克以“Dailiport”品牌上市，在義大利和西班牙以“Conferoport”品牌上市。

此外，市場上的主要企業正專注於非內部成長策略，例如分銷他Tacrolimus產品，預計這將推動預測期內的市場成長。例如，2022年1月，總部位於澳洲的專業製藥公司緬因製藥Group Limited宣佈在美國推出0.1%Tacrolimus軟膏。Tacrolimus軟膏是普特彼（Protopic）的學名藥，用於治療異位性皮膚炎。

本次調查的主要特點。

• 本報告對全球Tacrolimus市場進行了詳細分析，以 2021 年為基準年，給出了預測期（2022-2030 年）的市場規模和復合年成長率。
• 本報告指出了各個細分市場的潛在商機，並說明了該市場中具有吸引力的投資提案矩陣。
• 此外，本研究還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要企業採取的競爭策略的重要見解。
• 本報告根據以下參數介紹了全球Tacrolimus市場的主要企業概況：公司概況、產品系列、主要亮點、財務表現和策略。
• 透過利用本報告中提出的見解，企業行銷負責人和經營團隊將能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
• 本報告面向該產業的各類相關人員，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。 ¹
• 相關人員可以透過利用全球Tacrolimus市場分析中使用的各種策略矩陣，更輕鬆地做出決策。

目錄

第1章：研究目標與前提條件

• 研究目標
• 前提
• 簡稱

第2章 市場範圍

• 報告摘要
  • 市場定義和範圍
• 執行摘要
• Coherent Opportunity Map（COM）

第3章：市場動態、監管與趨勢分析

• 市場動態
  • 促進因素
  • 阻礙因素
  • PEST分析
  • 波特五力分析
  • 市場機遇
  • 法規環境
  • 主要進展
  • 產業趨勢

第4章 全球Tacrolimus市場：依產品類型分類，2026-2033年

• Tacrolimus膠囊和片劑
• Tacrolimus軟膏
• Tacrolimus注射液
• Tacrolimus顆粒

第5章 全球Tacrolimus市場：依應用領域分類，2026-2033年

• 免疫抑制
• 皮膚炎
• 其他

第6章 全球Tacrolimus市場：依最終用戶分類，2026-2033年

• 器官移植中心
• 醫院
• 診所
• 其他

第7章 全球Tacrolimus市場：依地區分類，2026-2033年

• 北美洲
  • 美國
  • 加拿大
• 拉丁美洲
  • 巴西
  • 阿根廷
  • 墨西哥
  • 其他拉丁美洲
• 歐洲
  • 英國
  • 德國
  • 義大利
  • 法國
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • ASEAN
  • 澳洲
  • 韓國
  • 亞太其他地區
• 中東
  • 海灣合作理事會國家
  • 以色列
  • 其他中東國家
• 非洲
  • 南非
  • 北非
  • 中非

第8章 競爭情勢

• 熱圖分析
• 市佔率分析（3x3矩陣）
• 公司簡介
  • Novartis AG
  • Mylan NV
  • Astellas Pharma Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Pfizer Inc.
  • Abbott
  • Senju Pharmaceutical Co. Ltd.
  • Glenmark Pharmaceuticals Ltd.
  • Lupin Limited
  • Vibcare Pharma Pvt. Ltd.

第9章 分析師建議

• 機會
• 分析師意見
• Coherent Opportunity Map

第10章

• 參考
• 調查方法

Tacrolimus Market is estimated to be valued at USD 12.7 Bn in 2026 and is expected to reach USD 16.6 Bn by 2033, growing at a compound annual growth rate (CAGR) of 7.2% from 2026 to 2033.

Tacrolimus is a calcineurin inhibitor and potent immunosuppressive drug that is primarily used to prevent cellular rejection following organ transplantation. It is also used topically to treat severe atopic dermatitis, severe refractory uveitis following bone marrow transplants, and the skin disorder vitiligo. Tacrolimus is available in capsule, granules for oral suspension (to be combined with liquid), extended-release (long acting) capsule, and extended-release tablet for oral administration. Tacrolimus immediate-release formulations, in combination with other immunosuppressants, are approved for the prevention of organ rejection in adult and pediatric patients receiving allogeneic liver, kidney, heart, or lung transplants. Tacrolimus extended-release formulations are approved for the prevention of organ rejection in adult and pediatric patients having kidney transplants when combined with other immunosuppressants, and may be used in patients who have been converted from immediate-release formulations.

Market Dynamics

The increasing product launch by the key players in the market is expected to drive the market growth over the forecast period. For instance, in June 2020, Sandoz, a Novartis division and a global leader in generic pharmaceuticals and biosimilars, announced the launch of once-daily generic tacrolimus capsules known as Dailiport in Germany, the U.K., The Netherlands, Finland, Sweden, Estonia, Latvia, and Slovakia, and as Conferoport in Italy and Spain.

Moreover, key companies in the market are focusing on inorganic growth strategies such as distribution of tacrolimus products, which is expected to drive the market growth over the forecast period. For instance, in January 2022, Mayne Pharma Group Limited, an Australia-based specialty pharmaceutical company announced that it had begun distribution of tacrolimus ointment, 0.1% in the U.S. Tacrolimus ointment is a generic version of PROTOPIC, indicated for the treatment of Atopic dermatitis.

Key features of the study

• This report provides an in-depth analysis of the global tacrolimus market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global tacrolimus market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Novartis AG, Mylan N.V., Astellas Pharma Inc., Dr. Reddy's Laboratories Ltd., Pfizer Inc., Abbott, Senju Pharmaceutical Co. Ltd., Glenmark Pharmaceuticals Ltd., Lupin Limited, and Vibcare Pharma Pvt. Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global tacrolimus market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts1
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global tacrolimus market

Market Segmentation

• By Product Type
  • Tacrolimus Capsules and Tablets
  • Tacrolimus Ointment
  • Tacrolimus Injection
  • Tacrolimus Granules
• By Application
  • Immunosuppression
  • Dermatitis
  • Others
• By End User
  • Organ Transplant Centers
  • Hospitals
  • Clinics
  • Others
• By Regional Insights
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
  • Novartis AG
  • Mylan N.V.
  • Astellas Pharma Inc.
  • Reddy's Laboratories Ltd.
  • Pfizer Inc.
  • Abbott
  • Senju Pharmaceutical Co. Ltd.
  • Glenmark Pharmaceuticals Ltd.
  • Lupin Limited
  • Vibcare Pharma Pvt. Ltd.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Product Type
  • Market Snippet, By Application
  • Market Snippet, By End User
  • Market Snippet, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • PEST Analysis
  • PORTER's Five Forces Analysis
  • Market Opportunities
  • Regulatory Scenario
  • Key Developments
  • Industry Trend

4. Global Tacrolimus Market, By Product Type, 2026-2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Tacrolimus Capsules and Tablets
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Tacrolimus Ointment
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Tacrolimus Injection
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Tacrolimus Granules
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends

5. Global Tacrolimus Market, By Application, 2026-2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Immunosuppression
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Dermatitis
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Others
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends

6. Global Tacrolimus Market, By End User, 2026-2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Organ Transplant Centers
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Hospitals
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Clinics
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Others
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends

7. Global Tacrolimus Market, By Region, 2026-2033, (USD Bn)

• Introduction
  • Market Share Analysis, By Region, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, For Region, 2021 - 2033
• North America
  • Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
  • Y-o-Y Growth Analysis, For Country, 2021 - 2033
  • Market Size and Forecast, By Product Type, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Application, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By End User, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
  • Y-o-Y Growth Analysis, For Country, 2021 - 2033
  • Market Size and Forecast, By Product Type, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Application, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By End User, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
  • Y-o-Y Growth Analysis, For Country, 2021 - 2033
  • Market Size and Forecast, By Product Type, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Application, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By End User, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
  • Y-o-Y Growth Analysis, For Country, 2021 - 2033
  • Market Size and Forecast, By Product Type, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Application, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By End User, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
  • Y-o-Y Growth Analysis, For Country, 2021 - 2033
  • Market Size and Forecast, By Product Type, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Application, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By End User, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Market Share Analysis, By Country/Region, 2025, 2028 and 2033 (%)
  • Y-o-Y Growth Analysis, For Country/Region, 2021 - 2033
  • Market Size and Forecast, By Product Type, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Application, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By End User, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
    • South Africa
    • North Africa
    • Central Africa

8. Competitive Landscape

• Heat Map Analysis
• Market Share Analysis (3x3 Matrix)
• Company Profiles
  • Novartis AG
    • Company Overview
    • Product Type Portfolio
    • Recent Developments/Updates
  • Mylan N.V.
    • Company Overview
    • Product Type Portfolio
    • Recent Developments/Updates
  • Astellas Pharma Inc.
    • Company Overview
    • Product Type Portfolio
    • Recent Developments/Updates
  • Dr. Reddy's Laboratories Ltd.
    • Company Overview
    • Product Type Portfolio
    • Recent Developments/Updates
  • Pfizer Inc.
    • Company Overview
    • Product Type Portfolio
    • Recent Developments/Updates
  • Abbott
    • Company Overview
    • Product Type Portfolio
    • Recent Developments/Updates
  • Senju Pharmaceutical Co. Ltd.
    • Company Overview
    • Product Type Portfolio
    • Recent Developments/Updates
  • Glenmark Pharmaceuticals Ltd.
    • Company Overview
    • Product Type Portfolio
    • Recent Developments/Updates
  • Lupin Limited
    • Company Overview
    • Product Type Portfolio
    • Recent Developments/Updates
  • Vibcare Pharma Pvt. Ltd.
    • Company Overview
    • Product Type Portfolio
    • Recent Developments/Updates

9. Analyst Recommendation

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

10. Section

• References
• Research Methodology
• About Us and Sales Contact